ATE291582T1 - Verfahren zur synthese von nukleosidanaloga - Google Patents

Verfahren zur synthese von nukleosidanaloga

Info

Publication number
ATE291582T1
ATE291582T1 AT00303892T AT00303892T ATE291582T1 AT E291582 T1 ATE291582 T1 AT E291582T1 AT 00303892 T AT00303892 T AT 00303892T AT 00303892 T AT00303892 T AT 00303892T AT E291582 T1 ATE291582 T1 AT E291582T1
Authority
AT
Austria
Prior art keywords
synthesis
nucleoside analogs
nucleoside
analogs
Prior art date
Application number
AT00303892T
Other languages
German (de)
English (en)
Inventor
Robert William Scott
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE291582T1 publication Critical patent/ATE291582T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AT00303892T 1999-05-11 2000-05-09 Verfahren zur synthese von nukleosidanaloga ATE291582T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13365199P 1999-05-11 1999-05-11

Publications (1)

Publication Number Publication Date
ATE291582T1 true ATE291582T1 (de) 2005-04-15

Family

ID=22459680

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00303892T ATE291582T1 (de) 1999-05-11 2000-05-09 Verfahren zur synthese von nukleosidanaloga

Country Status (22)

Country Link
US (1) US6271370B1 (esLanguage)
EP (1) EP1052264B1 (esLanguage)
JP (1) JP2001011092A (esLanguage)
KR (1) KR100403900B1 (esLanguage)
CN (1) CN1275575A (esLanguage)
AR (1) AR028991A1 (esLanguage)
AT (1) ATE291582T1 (esLanguage)
AU (1) AU3401100A (esLanguage)
BR (1) BR0002089A (esLanguage)
CA (1) CA2307951A1 (esLanguage)
CZ (1) CZ20001710A3 (esLanguage)
DE (1) DE60018833D1 (esLanguage)
HU (1) HUP0001843A3 (esLanguage)
ID (1) ID25992A (esLanguage)
IL (1) IL136027A0 (esLanguage)
IN (1) IN186850B (esLanguage)
MX (1) MXPA00004532A (esLanguage)
PL (1) PL340109A1 (esLanguage)
RU (1) RU2200738C2 (esLanguage)
TR (1) TR200001340A2 (esLanguage)
YU (1) YU25500A (esLanguage)
ZA (1) ZA200002263B (esLanguage)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
PL1773856T3 (pl) * 2004-07-21 2013-01-31 Gilead Pharmasset Llc Sposób otrzymywania alkilo-podstawionych 2-deoksy-2-fluoro-D-rybofuranozylo-pirymidyn i -puryn oraz ich pochodnych
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
ATE541848T1 (de) * 2005-05-05 2012-02-15 Ardea Biosciences Inc Diaryl-purin, azapurine und deazapurine als nichtnukleoside reverse-transkriptase-inhibitoren zur behandlung von hiv
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
BRPI0614290A2 (pt) 2005-08-08 2011-03-22 Argenta Discovery Ltd derivados de biciclo [ 2.2.1 ] hept-7-ilamina e seus usos
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
KR20080049113A (ko) 2005-10-21 2008-06-03 노파르티스 아게 Ｉｌ-13에 대항한 인간 항체 및 치료적 용도
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
KR20090073121A (ko) 2006-09-29 2009-07-02 노파르티스 아게 Ｐｉ3ｋ 지질 키나제 억제제로서의 피라졸로피리미딘
BRPI0718266A2 (pt) 2006-10-30 2014-01-07 Novartis Ag Compostos heterocíclicos como agentes anti-inflamatórios.
CA2707785C (en) 2007-12-14 2015-11-03 Pulmagen Therapeutics (Asthma) Limited Indoles and their therapeutic use
CA2709176C (en) * 2007-12-14 2013-02-05 Ardea Biosciences, Inc. Reverse transcriptase inhibitors
PT2231642E (pt) 2008-01-11 2014-03-12 Novartis Ag Pirimidinas como inibidores de quinase
US20110281917A1 (en) 2009-01-29 2011-11-17 Darrin Stuart Substituted Benzimidazoles for the Treatment of Astrocytomas
GB0902648D0 (en) 2009-02-17 2009-04-01 Argenta Discovery Ltd Pharmaceutical compounds and compositions
CA2752693A1 (en) 2009-02-17 2010-08-26 Chiesi Farmaceutici S.P.A. Triazolopyridine derivatives as p38 map kinase inhibitors
WO2011005860A2 (en) * 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. 5' phosphate mimics
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
WO2011018454A1 (en) 2009-08-12 2011-02-17 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
IN2012DN01961A (esLanguage) 2009-08-17 2015-08-21 Intellikine Llc
MX2012002179A (es) 2009-08-20 2012-03-16 Novartis Ag Compuestos heterociclicos de oxima.
GB201009731D0 (en) 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
WO2012116217A1 (en) 2011-02-25 2012-08-30 Irm Llc Compounds and compositions as trk inhibitors
US9062045B2 (en) 2011-09-15 2015-06-23 Novartis Ag Triazolopyridine compounds
WO2013078440A2 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
DK2788349T3 (en) 2011-12-09 2017-01-30 Chiesi Farm Spa kinase inhibitors
SG10201604656YA (en) 2011-12-09 2016-07-28 Chiesi Farma Spa Kinase inhibitors
KR20140103925A (ko) 2011-12-09 2014-08-27 키에시 파르마슈티시 엣스. 피. 에이. 4-히드록시-1,2,3,4-테트라히드로나프탈렌-1-일 우레아 및 호흡기 질환의 치료에서의 이들의 용도
MX371119B (es) 2012-04-03 2020-01-17 Novartis Ag Productos de combinacion con los inhibidores de cinasa de tirosina y su uso.
AU2013282869B2 (en) 2012-06-29 2015-12-24 Pfizer Inc. Novel 4-(substituted-amino)-7H-pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
WO2014195402A1 (en) 2013-06-06 2014-12-11 Chiesi Farmaceutici S.P.A. Kinase inhibitors
MA38884A1 (fr) 2013-09-05 2017-06-30 Hoffmann La Roche Composé de triazolopyridine, compositions et procédés d'utilisation associés
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
WO2015092592A1 (en) 2013-12-17 2015-06-25 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
MX373272B (es) 2014-07-31 2020-04-16 Novartis Ag Terapia de combinacion.
JP2018507236A (ja) 2015-03-04 2018-03-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ トリアゾロピリジン化合物及びその使用法
RU2722149C1 (ru) 2015-09-14 2020-05-27 Пфайзер Инк. Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
TW201720828A (zh) 2015-11-23 2017-06-16 赫孚孟拉羅股份公司 治療性化合物及組合物以及其使用方法
AR107165A1 (es) 2015-12-23 2018-03-28 Chiesi Farm Spa Inhibidores de quinasa
AR107164A1 (es) 2015-12-23 2018-03-28 Chiesi Farm Spa INHIBIDORES DE QUINASA p38
WO2017108736A1 (en) 2015-12-23 2017-06-29 Chiesi Farmaceutici S.P.A. N-[3-(3-{4-[[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl} -ureido)-phenyl]-methanesulfonamide derivatives and their use as p38 mapk inhibitors
EP3452464B1 (en) 2016-05-05 2021-12-15 F. Hoffmann-La Roche AG Pyrazole derivatives, compositions and therapeutic use thereof
SG11201901954XA (en) 2016-09-06 2019-04-29 Hoffmann La Roche 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof
CN110114343B (zh) 2016-12-29 2022-09-06 豪夫迈·罗氏有限公司 吡唑并嘧啶化合物及其使用方法
CN110494434B (zh) 2017-03-14 2022-05-24 豪夫迈·罗氏有限公司 吡唑并氯苯基化合物、其组合物及其使用方法
JP7228318B6 (ja) 2017-05-22 2023-03-10 エフ． ホフマン－ラ ロシュ アーゲー 処置用化合物及び組成物、並びにその使用方法
CA3061236A1 (en) 2017-05-22 2018-11-29 F. Hoffmann-La Roche Ag Therapeutic compounds and compositions, and methods of use thereof
US10364245B2 (en) 2017-06-07 2019-07-30 Chiesi Farmaceutici S.P.A. Kinase inhibitors
CN111587250A (zh) 2018-01-15 2020-08-25 豪夫迈·罗氏有限公司 作为jak抑制剂的吡唑并嘧啶化合物
EP3801069A4 (en) 2018-06-01 2022-03-16 Cornell University MULTIPLE THERAPY FOR DISEASE OR DISORDER ASSOCIATED WITH PI3K
PE20220577A1 (es) 2019-06-18 2022-04-20 Hoffmann La Roche Inhibidores de jak cinasas basados en pirazolopirimidina sulfona y usos de los mismos
EP3986900A1 (en) 2019-06-18 2022-04-27 F. Hoffmann-La Roche AG Tetrazole-substituted pyrazolopyrimidine inhibitors of jak kinases and uses thereof
WO2020257143A1 (en) 2019-06-18 2020-12-24 Genentech, Inc. Pyrazolopyrimidine aryl ether inhibitors of jak kinases and uses thereof
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
CN117343119A (zh) * 2022-06-29 2024-01-05 上海交通大学 一种烷基化核苷、核苷酸、寡核苷酸及其类似物的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61207400A (ja) * 1985-03-11 1986-09-13 Nippon Zoki Pharmaceut Co Ltd ヌクレオシド化合物の製造方法
US4751292A (en) 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
US4859677A (en) 1987-04-17 1989-08-22 University Of Kansas Nucleoside analogues having antiviral activity
US5246931A (en) 1988-10-25 1993-09-21 Bristol-Myers Squibb Company Carbocyclic nucleoside analogs
US5688778A (en) 1989-05-15 1997-11-18 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Nucleoside analogs
GB8916480D0 (en) 1989-07-19 1989-09-06 Glaxo Group Ltd Chemical process
US5763596A (en) 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. C-4' modified adenosine kinase inhibitors
US5674998A (en) 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
US5726302A (en) * 1989-09-15 1998-03-10 Gensia Inc. Water soluble adenosine kinase inhibitors
US5276151A (en) 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5470857A (en) 1990-09-14 1995-11-28 Marion Merrell Dow Inc. Carbocyclic nucleoside analogs useful as immunosuppressants
SE9003151D0 (sv) 1990-10-02 1990-10-02 Medivir Ab Nucleoside derivatives
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9204015D0 (en) 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
TW374087B (en) 1993-05-25 1999-11-11 Univ Yale L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents
AU3086495A (en) * 1994-08-02 1996-03-04 Banyu Pharmaceutical Co., Ltd. Antitumor indolopyrrolocarbazoles
US5659023A (en) 1995-02-01 1997-08-19 Gilead Sciences, Inc. Nucleotide analogues
BR9707185A (pt) 1996-01-23 1999-03-23 Glaxo Group Ltd Nucleosídeos de benzimidazol modificados como agentes antivirais

Also Published As

Publication number Publication date
JP2001011092A (ja) 2001-01-16
CN1275575A (zh) 2000-12-06
EP1052264B1 (en) 2005-03-23
RU2200738C2 (ru) 2003-03-20
TR200001340A2 (tr) 2000-12-21
IL136027A0 (en) 2001-05-20
IN186850B (esLanguage) 2001-11-24
HUP0001843A2 (hu) 2001-06-28
ID25992A (id) 2000-11-16
AU3401100A (en) 2000-11-16
CA2307951A1 (en) 2000-11-11
CZ20001710A3 (cs) 2001-09-12
AR028991A1 (es) 2003-06-04
BR0002089A (pt) 2001-01-02
US6271370B1 (en) 2001-08-07
PL340109A1 (en) 2000-11-20
ZA200002263B (en) 2001-12-24
KR100403900B1 (ko) 2003-11-01
HU0001843D0 (en) 2000-07-28
MXPA00004532A (es) 2002-03-08
DE60018833D1 (de) 2005-04-28
HUP0001843A3 (en) 2001-09-28
KR20010069193A (ko) 2001-07-23
EP1052264A2 (en) 2000-11-15
EP1052264A3 (en) 2001-06-13
YU25500A (sh) 2003-08-29

Similar Documents

Publication Publication Date Title
ATE291582T1 (de) Verfahren zur synthese von nukleosidanaloga
EP1066308A4 (en) IMPROVED METHODS OF SYNTHESIS OF OLIGONUCLEOTIDES
ATE272613T1 (de) Verfahren zur synthese von cox-2 inhibitoren
EP1427743A4 (en) SYNTHESIS OF PYRAZOLOPYRIMIDINES
ATE388132T1 (de) Verfahren zur hydroformylierung von olefinen
DK0757684T3 (da) Fremgangsmåde til diastereoselektiv syntese af nucleosidanaloger
ATE369201T1 (de) Verfahren zur reinigung von synthesegas
DE59608364D1 (de) Verfahren zur selektiven Synthese von Silylalkyldisulfiden
ATE499153T1 (de) Verfahren zur vorhydrolyse von biomasse
DE60012979D1 (de) Verfahren zur selektiven dimerisierung von isobuten
DE69911195D1 (de) Verfahren zur direktoxidation von olefinen zu olefinoxiden
EP0979233A4 (en) Method for solution phase synthesis of oligonucleotides
DE50002724D1 (de) Verfahren zur querstromfiltration
DE60327356D1 (de) Verfahren zur synthese von metallnanoteilchen
EP1246833A4 (en) IMPROVED SYNTHESIS OF SULFUR OLIGONUCLEOTIDES
ATE437486T1 (de) Verfahren zur konfiguration von physischen kanälen
DE60012910D1 (de) Verfahren zur trennung von olefinen von gesättigten kohlenwasserstoffen
DE60028076D1 (de) Verfahren zur stereoselektiven synthese zyklischer aminosäuren
DE60201384D1 (de) Verfahren zur Synthese von Harnstoff
DE69824366D1 (de) Verfahren zur Synthese von Alkylpolyglucosiden
DE69817550D1 (de) Verfahren zur sprachsynthese
DE60010753D1 (de) Verfahren zur reinigung von lactamen
DE60117687D1 (de) Verfahren zur synthese von pfropfpolymeren
DE59900737D1 (de) Verfahren zur Synthese von Feststoffen
DE69232830D1 (de) Verfahren zur Synthese von D(+)-Biotin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties